Project Grant R21DE033510
Award Date
9/5/24
Completion Date
8/31/26
Dollars Obligated
$808K
Federal Agency
National Institute of Dental and Craniofacial Research
Federal Grant Program
93.121
Assistance Type
Project Grant
Place of Performance
South Carolina, USA
Similar Awards
This federal Project Grant award, valued at $274,100.00 and funded by the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121), aims to investigate the role of Protease-Activated Receptor 2 (PAR2) in oral cancer pain. The key objectives are to: 1) Determine the impact of oral cancer on PAR2 trafficking and signaling in trigeminal neurons, and 2) Develop nanoparticles to target PAR2 located at specific cellular...
This federal Project Grant award in the amount of $469,830.00 was provided by the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121). The grant aims to identify oral bacterial species with anti-cancer properties and evaluate their potential for preventing or treating oral squamous cell carcinoma (OSCC). Specifically, the study will assess the effects of Streptococcus mitis and Haemophilus parainfluenzae on OSCC...
This $390,000 Project Grant award under the National Institute of Dental and Craniofacial Research's (NIDCR) Oral Diseases and Disorders Research program (CFDA 93.121) supports research at the Medical College of Wisconsin, Inc. to leverage single-cell co-culture and gene expression profiling techniques for identifying tumor antigen-specific T cells in oral squamous cell carcinoma (OSCC). The key objectives are to: 1) Use a high-throughput single-cell co-culture system to isolate and identify...
This Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), provides $799,270 to Keraceuticals, Inc. to develop novel 1,3-thiourea anticancer compounds for the treatment of oral squamous cell carcinoma (OSCC). The key products and services under this award are: Formulating the lead compound CIDD99 for oral and/or intravenous administration, and rapidly assessing the pharmacokinetics and...
This $598,332 Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research (CFDA 93.121) program, will support research to investigate the role of the truncated TrkB isoform (TrkBT1) in oral cancer pain. The primary awardee, the University of Texas Health Science Center at San Antonio (UTHSCSA), will conduct studies to examine how TrkBT1 expressed in trigeminal sensory neurons and oral squamous cell carcinoma (OSCC)...
The National Institute of Dental and Craniofacial Research (NIDCR) awarded a $204,688 Project Grant under the Oral Diseases and Disorders Research federal grant program (CFDA 93.121) to The Johns Hopkins University. The grant will fund the development and evaluation of a novel cancer immunotherapy approach involving Salmonella-derived nanoparticles (SOMV-9RE7) combined with albumin-fused cytokines (ALB-FLT3L and ALB-IFNB). The project aims to enhance dendritic cell-mediated T cell immunity...
This Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), provides $294,505 to support the development and commercialization of a targeted fluorescence dye for intraoperative imaging and precision surgical treatment of head and neck cancer (HNC). The goal is to create a small peptide-based fluorescent probe that can specifically stain HNC tumors to assist surgeons in identifying tumors...
This federal Project Grant award, valued at $164,322.00, was provided by the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121). The award supports research to investigate the evolution of pro-tumoral myeloid cells during the transition from oral epithelial dysplasia to head and neck squamous cell carcinoma, with a focus on the role of the SOX2 oncogene and its impact on the STING immune signaling pathway. The...
This federal Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), will support research to improve understanding of oral cancer pain mechanisms. The $162,743 award, effective March 10, 2025 through February 28, 2030, will enable New York University (NYU) to: Develop and validate new methods to measure pressure and stretch sensitivity in oral cancer patients, providing novel insights into...
This Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), totals $499,105 and will support research to develop novel microRNA-based therapeutics to enhance bone regeneration and suppress tumor growth in oral cancer patients undergoing radiation therapy. The key goals are to determine the functions of microRNA-200c in promoting mandibular bone regeneration under radiation conditions and...